Azenta, Inc. (AZTA)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$31.33+0.48%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · AZTA
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 11 valuation methods, at three horizons. As of 2026-09-06. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $31 AZTA trades at 75× p/e — 2.2× the 34× p/e peer median. The market is re-rating it beyond its own range; our $15 fair value is low-confidence here. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| dcf fcfe | 12M | $8.48 | — | — | Analyst | high |
| dcf fcff | 12M | $12.67 | — | — | Analyst | high |
| ddm gordon | 12M | $3.15 | — | — | TTM | high |
| graham number | 12M | $17.75 | — | — | TTM | high |
| Peer EV/EBITDA | 12M |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Bottom 25% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
Only expensive valuation — not the full expensive x weak x turbulent stack. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks more expensive than peers.
Self-history needs ~20 months of data.
Trailing four: 2025-Q4, 2026-Q1, 2026-Q2, 2026-Q3
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| $9.68 |
| 18.0 |
| 0.30 |
| TTM |
| high |
| Peer P/FCF | 12M | $7.21 | 33.1 | 0.22 | TTM | high |
| Peer P/E | 12M | $14.24 | 33.9 | 0.42 | TTM | high |
| Peer P/S | 12M | $77.35 | 5.7 | 13.55 | TTM | high |
| PEG | 12M | $32.16 | 76.6 | 0.42 | TTM | high |
| residual income | 12M | $23.47 | — | — | TTM | high |
| triangulated | 12M | $16.20 | 33.9 | 0.48 | Triangulated | high |
| Peer P/E | 3Y | $28.80 | 33.9 | 0.85 | Analyst | medium |
| Peer P/S | 3Y | $81.04 | 5.7 | 14.20 | guidance | medium |
| PEG | 3Y | $65.04 | 76.6 | 0.85 | Analyst | medium |
| Peer P/E | 5Y | $28.96 | 33.9 | 0.85 | Analyst | medium |
| Peer P/S | 5Y | $81.48 | 5.7 | 14.28 | guidance | medium |
| PEG | 5Y | $65.40 | 76.6 | 0.85 | Analyst | medium |